SCHEMBL7183230

SCHEMBL7183230

COP(=O)(OC)c1cc(-c2ccc(C)cc2)ccc1OS(=O)(=O)C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN5 P54829 1/20 0.36
▸ DRD2 P14416 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD5 P21918 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ HPGD P15428 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ALKBH3 Q96Q83 2/20 0.32
▸ ESR2 Q92731 1/20 0.31
▸ ACLY P53396 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ IDO1 P14902 1/20 0.31
▸ KIF11 P52732 1/20 0.31
▸ AR P10275 1/20 0.31
▸ PTGS2 P35354 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527196 0.79 ALDH1A1 (0.43) ALDH1A1HPGDLMNAALKBH3
SCHEMBL7188818 0.73 CFD (0.45) ALDH1A1HPGDLMNA
SCHEMBL7188341 0.72 PTPN11 (0.40) ALDH1A1LMNA
SCHEMBL7195829 0.71 MGAM (0.37) ALDH1A1HPGDLMNAHTTALKBH3
SCHEMBL13954072 0.71 CYP19A1 (0.40) ALKBH3ESR2CA2PTGS2SDHB
SCHEMBL7183095 0.70 MCL1 (0.47) PTPN5ALDH1A1HPGD
SCHEMBL4581096 0.70 ACHE (0.55) ALDH1A1HPGDLMNACA1CA2
SCHEMBL17536908 0.70 ALKBH3 (0.46) PTPN5ALKBH3PTGS2KCNH2
SCHEMBL7600097 0.70 HPRT1 (0.43) PTPN5HPGDLMNAHTTALKBH3
SCHEMBL2989290 0.70 CA1 (0.44) DRD2DRD1DRD4DRD5DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 — — EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 — — US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 — — US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO PTPN5 16/4885DRD2 4719/4885DRD1 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback